BUSINESS WIRE
HUENENBERG, Switzerland--(BUSINESS WIRE)--July 11, 2008--Alcon,
Inc. (NYSE:ACL) announced today it has terminated the development
program designed to evaluate the benefit of anecortave acetate
treatment on the risk for developing sight-threatening choroidal
neovascularization secondary to age-related macular degeneration. The
decision followed a planned interim analysis of studies C-02-60 A and
B that was performed after 2,546 patients had completed the 24 month
time point. In this analysis, anecortave acetate showed no effect on
the primary or secondary endpoints. In addition to terminating studies
C-02-60 A and B, the company also terminated two smaller studies with
an identical design that were being conducted in Asia, C-04-30 and
C-05-34.
The company continues to study anecortave acetate administered as
an anterior juxtascleral depot to reduce intraocular pressure in
patients with open-angle glaucoma.
About Alcon
Alcon, Inc. is the world's leading eye care company, with sales of
approximately $5.6 billion in 2007. Alcon, which has been dedicated to
the ophthalmic industry for more than 60 years, researches, develops,
manufactures and markets pharmaceuticals, surgical equipment and
devices, contact lens care solutions and other vision care products
that treat diseases, disorders and other conditions of the eye.
Alcon's majority shareholder is Nestle, S.A., the world's largest food
company. For more information on Alcon Inc., visit the company's Web
site at www.alcon.com.
Caution Concerning Forward-Looking Statements. This press release
contains forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. These statements involve
known and unknown risks, uncertainties and other factors which may
cause our actual results, performance or achievements to be materially
different from any future results, performances or achievements
expressed or implied by our forward-looking statements. These
statements reflect the views of our management as of the date of this
press release with respect to future events and are based on
assumptions and subject to risks and uncertainties. Given these
uncertainties, you should not place undue reliance on these
forward-looking statements. You should read this press release with
the understanding that our actual future results may be materially
different from what we expect. Except to the extent required under the
federal securities laws and the rules an regulations promulgated by
the Securities and Exchange Commission, we undertake no obligation to
publicly update or revise any of these forward-looking statements,
whether to reflect new information or future events or circumstances
or otherwise.
CONTACT: Alcon Investor Relations
Doug MacHatton, 800-400-8599
[email protected]
www.alcon.com